Successfully treated thrombocytopenia following allogeneic transplant with daratumumab: a case report and literature review

A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations. A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.